Yeow Tee Goh
A5028165330- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Eosinophilic Disorders and Syndromes
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Hematopoietic Stem Cell Transplantation
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Complement system in diseases
- Peptidase Inhibition and Analysis
- Protein Degradation and Inhibitors
- CNS Lymphoma Diagnosis and Treatment
- T-cell and B-cell Immunology
- Renal Diseases and Glomerulopathies
- Immunotherapy and Immune Responses
- Neutropenia and Cancer Infections
- Hemoglobinopathies and Related Disorders
- Cytomegalovirus and herpesvirus research
- Histone Deacetylase Inhibitors Research
- Kruppel-like factors research
- HER2/EGFR in Cancer Research
Singapore General Hospital
2016-2025
National Cancer Centre Singapore
2023-2024
Duke-NUS Medical School
2007-2024
SingHealth
2023
National University of Singapore
2022
SingHealth Duke-NUS Academic Medical Centre
2018-2021
Palmetto Hematology Oncology
2015
Bristol-Myers Squibb (Germany)
2007
Abstract Asciminib targets the BCR::ABL1 myristoyl pocket, maintaining activity against T315I , which is resistant to most approved adenosine triphosphate–competitive tyrosine kinase inhibitors. We report updated phase I results (NCT02081378) assessing safety/tolerability and antileukemic of asciminib monotherapy 200 mg twice daily in 48 heavily pretreated patients with T315I-mutated chronic-phase chronic myeloid leukemia (CML-CP; data cutoff: January 6, 2021). With 2 years’ median exposure,...
Abstract BACKGROUND: In a phase 3 study, the authors assessed effects of dasatinib at doses 140 mg once daily and 70 twice in patients who had either chronic myeloid leukemia (CML) advanced phases or Philadelphia chromosome‐positive acute lymphoblastic were resistant intolerant to imatinib. current report, results for with CML blast after 2 years follow‐up are reported. METHODS: Patients stratified according whether they (MBP‐CML) lymphoid (LBP‐CML) randomized (1:1) within each stratum...
Hematopoietic stem-cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a serious complication with significant mortality and no approved therapy. HSCT-TMA results from endothelial injury, which activates the lectin pathway of complement. Narsoplimab (OMS721), an inhibitor mannan-binding lectin-associated serine protease-2 (MASP-2), was evaluated for safety efficacy in adults HSCT-TMA.In this single-arm open-label pivotal trial (NCT02222545), patients received intravenous...
Abstract Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease characterized by complement-mediated hemolysis. Pegcetacoplan the first C3-targeted therapy approved for adults with PNH (United States), inadequate response or intolerance to C5 inhibitor (Australia), and anemia despite C5-targeted ≥3 months (European Union). PRINCE was phase 3, randomized, multicenter, open-label, controlled study evaluate efficacy safety of pegcetacoplan vs control (supportive care only; eg, blood...
Abstract Asciminib is approved for patients with Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia (CML-CP) who received ≥2 prior tyrosine kinase inhibitors or have the T315I mutation. We report updated results of a phase 1, open-label, nonrandomized trial (NCT02081378) assessing safety, tolerability, and antileukemic activity asciminib monotherapy 10–200 mg once twice daily in 115 CML-CP without (data cutoff: January 6, 2021). After ≈4-year median exposure, 69.6%...
BACKGROUND NVP‐AUY922 (AUY; Luminespib) with or without bortezomib showed preclinical activity against multiple myeloma (MM) cells. This phase 1/1B study assessed alone and in patients relapsed refractory MM. METHODS Dose escalation was guided by an adaptive Bayesian logistic regression model. In 1, who progressed after 2 to 4 prior therapies received intravenously once weekly. 1B, fewer plus bortezomib. The primary objective determine the maximum tolerated dose (MTD) of NVP‐AUY922. RESULTS...
Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia transfusion dependency among the most important negative prognostic factors exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF possesses a pharmacological clinical profile differentiated from other JAKi inhibition JAK1, JAK2 ACVR1. MMB is designed to address complex drivers iron-restricted anemia chronic inflammation should...
BackgroundPatients with neutropenic fever after 4–7 days of broad-spectrum antibiotics are given antifungals empirically. This strategy may lead to over-treatment.MethodsPatients hematological malignancies undergoing intensive chemotherapy or hematopoietic stem cell transplantation were randomized two arms. Patients in the 'preemptive' arm had regular galactomannan (GM) assays, and received caspofungin, amphotericin voriconazole (CAV) for persistent febrile neutropenia if they positive GM...
7002 Background: MMB, an oral JAK1/2 and ACVR1/ALK2 inhibitor, showed clinical activity on MF symptoms, RBC transfusion requirements (anemia), spleen volume in the SIMPLIFY trials. This pivotal phase 3 study of patients (pts) previously treated with a JAK inhibitor (JAKi) tested MMB vs DAN key symptom, anemia, endpoints at 24 weeks (wks). Methods: Eligibility: Primary or post-ET/PV MF; DIPSS high risk, Int-2, Int-1; Symptom Assessment Form Total Score (MFSAF TSS) ≥10; Hgb <10 g/dL; prior...
LBA6500 Background: We present primary results from ASC4FIRST (NCT04971226), the first study in CML comparing all current standard-of-care frontline TKIs with a novel agent, ASC, newly diagnosed pts. ASC Specifically Targets ABL Myristoyl Pocket (STAMP). Methods: Adults were randomly assigned 1:1 to receive 80 mg once daily or an IS TKI at standard label doses, stratified by ELTS risk category and prerandomization selected (PRS) (imatinib [IMA] second-generation [2G] TKIs), which was...
Abstract Asciminib is the first approved BCR::ABL1 inhibitor that Specifically Targets ABL Myristoyl Pocket (STAMP). The present final analysis of phase 1, open-label, nonrandomized trial (NCT02081378) assessed long-term safety, tolerability, and antileukemic activity asciminib in 115 patients with chronic myeloid leukemia without T315I mutation who received 10–200 mg twice daily (BID) or 80–200 once (cutoff: March 14, 2023). Median exposure duration was 5.9 (range, 0–8.4) years; 60.9%...
Data from in vitro and animal studies suggest that asciminib, the first BCR::ABL1 inhibitor Specifically Targets ABL Myristoyl Pocket (STAMP), synergizes with adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitors (TKIs) to prevent emergence of overcome resistance. Combination therapy may provide new treatment options for patients chronic myeloid leukemia (CML) suboptimal responses ATP-competitive TKI monotherapy. Preliminary analysis asciminib combined nilotinib, imatinib, or...